Health awareness observances, such as National Liver Health Awareness Month each October, provide clinicians with a timely opportunity to review current, evidence-based guidance for the diagnosis and management of a wide range of diseases. Incorporating awareness initiatives into clinical practice supports earlier detection and interventions, helping mitigate disease progression.

In recognition of National Liver Health Awareness Month, we are highlighting a selection of articles focused on liver-related topics that were recently published in medical journals.

Recently Published Journal Articles on Liver Health Topics

Bezafibrate for Primary Biliary Cholangitis: Time to Act on the Evidence

  • Nature Reviews, Gastroenterology & Hepatology, October 2025
  • Description: After the regulatory rejection of obeticholic acid, peroxisome proliferator-activated receptor agonists have emerged as the leading second-line candidates for primary biliary cholangitis, pending definitive approval. Of these, only bezafibrate, a low-cost, widely available generic, has demonstrated long-term efficacy — a fact largely disregarded.
  • Summary
  • Full Text

TAPP@NBs Combined with GSNO to Enhance the Anti-Liver Cancer Effect of Snondynamic Therapy

  • Biomedical Materials, October 2025
  • Description: Sonodynamic therapy (SDT) is a viable alternative to traditional photodynamic therapy owing to its ability to penetrate tissue. However, the therapeutic efficacy of a single SDT treatment is constrained by the prolonged hypoxia of the tumor, rendering SDT ineffective for treating disease. This paper describes a novel approach for optimizing tumor treatment.
  • Summary
  • Full Text

The Association Between Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Case-Control Study

  • BMC Pediatrics, October 2025
  • Description: Non-alcoholic fatty liver disease (NAFLD) is a growing concern among children and adolescents, with emerging evidence highlighting the role of gut microbiota in its pathogenesis. This case-control study aimed to explore the association between gut microbiota composition and NAFLD in overweight and obese Iranian children and adolescents.
  • Summary
  • Full Text

Effect of Statins and PCSK9 Inhibition on Metabolic Dysfunction-Associated Steatotic Liver Disease

  • Journal of Digestive Diseases, October 2025
  • Description: Dyslipidemia is common in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and, along with other metabolic comorbidities, accounts for an increased cardiovascular risk. Effective treatment of dyslipidemia not only reduces such risk but may have a beneficial effect on MASLD as well. In this article, researchers reviewed published data on the efficacy and safety of available hypolipidemic treatments for MASLD.
  • Summary
  • Full Text

Knowledge, Attitudes, and Practices Toward Fatty Liver Disease in Patients with Hepatitis B Combined Fatty Liver Disease

  • Scientific Reports, October 2025
  • Description: The objective of the study was to assess the knowledge, attitudes, and practices of patients with chronic hepatitis B combined with metabolic-associated fatty liver disease toward fatty liver disease.
  • Summary
  • Full Text

Incidence and Risk Factors of Symptomatic Venous Gas Embolism During Laparoscopic Liver Resection

  • Journal of Hepato-Biliary-Pancreatic Sciences, October 2025
  • Description: Risk factors of symptomatic venous gas embolism (GE) during laparoscopic liver resection (LLR) are poorly known. The objective of this study was to report the incidence, risk factors, and morbidity of symptomatic GE during LLR.
  • Summary
  • Full Text

Liraglutide-Induced Liver Injury: A Case Report and Review

  • Case Reports in Gastroenterology, October 2025
  • Description: Glucagon-like peptide-1 receptor agonists such as liraglutide have revolutionized the management of type 2 diabetes and obesity. The article presents a case of a 30-year-old woman who developed drug-induced liver injury to liraglutide, confirmed on histology, with resolution on cessation of liraglutide over six months.
  • Summary
  • Full Text

Liver Fibrosis with Persistently Normal Transaminase Levels Exhibits a Distinct Treatment Response in MASLD

  • BMJ Open Gastroenterology, October 2025
  • Description: Metabolic dysfunction-associated steatotic liver disease (MASLD) presents considerable variability in disease progression and treatment outcomes. The authors aimed to determine whether specific patterns of liver inflammatory flares are correlated with distinct treatment responses.
  • Summary
  • Full Text

Look forward to more journal rundowns in the coming weeks. 

Sign up for alerts and stay informed on the latest published articles and guidelines.

Copyright © 2025 Guideline Central, all rights reserved.